AsiaPharmaceutical-B (06855.HK) released its interim performance results, with a profit of 2.34 billion yuan. Sales of Nalnib (Orelbatinib) in China increased by 93% year-on-year.

Wisdom Finance APP News, AstraZeneca Pharmaceuticals-B (06855.HK) released its performance for the six months ending June 30, 2025, with a profit of 234 million yuan. The sales of Tagrisso (osimertinib) in China increased by 105 million yuan or 93% to 217 million yuan in the first half of 2025 compared to the six months ending June 30, 2024, which was 113 million yuan.